Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Regions Financial Corporation Common Stock (RF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Regions Financial Corporation Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Regions Financial Corporation Common Stock trades at $26.93 (market cap $23.01B). The key difference: Regions Financial Corporation Common Stock is far larger — about 23.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Regions Financial Corporation Common Stock pays a 4.05% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Regions Financial Corporation Common Stock for 6 Days on average.
| MRVI | RF | |
|---|---|---|
Market Cap | $972.90M | $23.01B |
Volume | 4,325,710 | 10,095,088 |
Sector | Health | Financials |
52-Week High | $9.00 | $32.40 |
52-Week Low | $2.83 | $23.35 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $20.75B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Regions Financial (RF) trades at $27.01, down 1.32% today, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 10.98, net income margin of 29.3%, and consistent earnings beats in recent quarters. Recent news highlights dividend declarations and upcoming Q3 earnings, while the company plans significant branch expansion.
The outlook is cautiously optimistic with a $32.78 consensus price target suggesting 21% upside. Key risks include elevated expenses and weaker capital markets revenue. Analyst sentiment is mixed with 40% buy ratings, but institutional interest remains strong with Bank of America's recent $219 million investment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Regions Financial Corporation Common Stock
Regions Financial is a financial holding company that operates through Regions Bank. It provides consumer, commercial, mortgage, wealth-management, and investment services across the South, Midwest, and Texas.
Read more on RF →
